British pharmaceutical giant AstraZeneca unveiled sharply higher year-on-year profit and sales on Thursday, driven by the integration of Alexion, despite the loss of momentum in revenues linked to the covid-19 vaccine.
The group's share of profit amounted to 3.3 billion dollars against 112 million a year earlier, for a turnover up 18.5% to 44.4 billion.